Anticoagulant reversal

Last updated: November 20, 2023

CME information and disclosurestoggle arrow icon

To see contributor disclosures related to this article, hover over this reference: [1]

Physicians may earn CME/MOC credit by searching for an answer to a clinical question on our platform, reading content in this article that addresses that question, and completing an evaluation in which they report the question and the impact of what has been learned on clinical practice.

AMBOSS designates this Internet point-of-care activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

For answers to questions about AMBOSS CME, including how to redeem CME/MOC credit, see "Tips and Links" at the bottom of this article.

Summarytoggle arrow icon

Anticoagulant reversal is a critical step in the management of patients with life-threatening bleeding who are taking an anticoagulant. The reversal agents indicated depend on the specific anticoagulant taken by the patient. The risk of thromboembolic events is increased by most reversal agents. For this reason, their use should be limited to cases of serious or life-threatening bleeding. All patients who undergo anticoagulation reversal should be monitored closely.

Overview of anticoagulant reversaltoggle arrow icon

Drug class Drug names Monitoring parameters [2] Half-life [2] Reversal agents [2][3]
Oral vitamin K antagonists
  • 36–48 hours
Heparins Unfractionated heparin
  • 60–90 minutes
Low molecular weight heparin
  • 3–6 hours
Synthetic pentasaccharide factor Xa inhibitors
  • 17–21 hours
Direct oral anticoagulants Direct thrombin inhibitors
  • 12–14 hours
Direct Xa inhibitors

Nonspecific reversal agents like 4-factor prothrombin complex concentrate (PCC), activated PCC, recombinant activated factor VII, thrombocyte concentrates, and fresh frozen plasma have procoagulatory effects! Before these drugs are administered, the increased risk of thrombosis should be carefully weighed against the risk of ongoing bleeding. [4]

Warfarin reversaltoggle arrow icon

The treatment strategy depends on whether the patient is symptomatic and if there is serious or life-threatening bleeding present. [3][5][6][7]

Active hemorrhage (regardless of INR) [3]

The large fluid volumes of FFP and the fact that it must be transfused shortly after thawing can cause fluid overload and TRALI.

Asymptomatic patient with elevated INR

Serum INR Recommended management [3][7]
INR greater than therapeutic range but < 5.0
  • Decrease dose or stop warfarin.
  • Monitor INR every 24 hours.
  • Once INR is within the therapeutic range, restart warfarin at the same or lower dose.
INR ≥ 5 but < 10
  • Stable patient with no increased risk of bleeding:
    • Stop warfarin.
    • Monitor INR every 24 hours.
    • Once INR is within the therapeutic range, restart warfarin at a 10–15% lower dose.
  • Stable patient at increased risk of bleeding:
INR ≥ 10
  • Stop warfarin.
  • Give high-dose oral vitamin K. [3]
  • Monitor INR every 24 hours.
  • Repeat oral vitamin K if INR remains elevated at 24 hours.
  • When INR is in the therapeutic range, restart warfarin at a dose that is 15–20% lower.

Heparin reversaltoggle arrow icon

General principles [3]

Reversal of unfractionated heparin and LMWH [3]

Protamine dosing for unfractionated heparin [3]

Time since last heparin dose Recommended IV protamine dose
< 30 minutes
30–60 minutes
> 120 minutes

Protamine dosing for LMWH [3]

  • Enoxaparin
    • Give IV protamine (dose per the table below).
    • If PTT remains elevated after 2–4 hours or bleeding persists, give a second, lower dose of protamine.
Time since enoxaparin dose Recommended IV protamine dose
< 8 hours
8–12 hours
> 12 hours

The total dose of protamine should never exceed 50 mg.

Reversal of fondaparinux

Both aPCC and recombinant activated factor VII increase the risk of thrombosis.

Direct oral anticoagulant reversaltoggle arrow icon

Reversal of dabigatran [3]

Reversal of factor Xa inhibitors (e.g., rivaroxaban, apixaban, edoxaban, betrixaban) [3]

PCC and aPCC increase the risk of thrombosis.

Acute management checklisttoggle arrow icon

Referencestoggle arrow icon

  1. Sartori MT, Prandoni P. How to effectively manage the event of bleeding complications when using anticoagulants. Expert Review of Hematology. 2015; 9 (1): p.37-50.doi: 10.1586/17474086.2016.1112733 . | Open in Read by QxMD
  2. Yee J, Kaide C. Emergency Reversal of Anticoagulation. West J Emerg Med. 2019; 20 (5): p.770-783.doi: 10.5811/westjem.2018.5.38235 . | Open in Read by QxMD
  3. Frontera JA, Lewin III JJ, Rabinstein AA, et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage. Neurocrit Care. 2015; 24 (1): p.6-46.doi: 10.1007/s12028-015-0222-x . | Open in Read by QxMD
  4. Shoeb M, Fang MC. Assessing bleeding risk in patients taking anticoagulants. J Thromb Thrombolysis. 2013; 35 (3): p.312-319.doi: 10.1007/s11239-013-0899-7 . | Open in Read by QxMD
  5. Garcia DA, Crowther MA. Reversal of Warfarin. Circulation. 2012; 125 (23): p.2944-2947.doi: 10.1161/circulationaha.111.081489 . | Open in Read by QxMD
  6. 2011 Clinical Practice Guide on Anticoagulant Dosing and Management of Anticoagulant Associated Bleeding Complications in Adults. Updated: January 1, 2011. Accessed: December 10, 2019.
  7. Awad NI, Cocchio C. Activated prothrombin complex concentrates for the reversal of anticoagulant-associated coagulopathy.. P T. 2013; 38 (11): p.696-701.
  8. $Contributor Disclosures - Anticoagulant reversal. All of the relevant financial relationships listed for the following individuals have been mitigated: Jan Schlebes (medical editor, is a shareholder in Fresenius SE & Co KGaA). None of the other individuals in control of the content for this article reported relevant financial relationships with ineligible companies. For details, please review our full conflict of interest (COI) policy:.
  9. Thomas S, Makris M. The reversal of anticoagulation in clinical practice .. Clin Med. 2018; 18 (4): p.314-319.doi: 10.7861/clinmedicine.18-4-314 . | Open in Read by QxMD
  10. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative Management of Antithrombotic Therapy. Chest. 2012; 141 (2): p.e326S-e350S.doi: 10.1378/chest.11-2298 . | Open in Read by QxMD
  11. Sunkara T, Ofori E, Zarubin V, Caughey ME, Gaduputi V, Reddy M. Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review. Health Serv Insights. 2016; 9s1: p.s25–36.doi: 10.4137/hsi.s40701 . | Open in Read by QxMD

Icon of a lockAccess full content

Sign up and get unlimited access.
 Evidence-based content, created and peer-reviewed by physicians. Read the disclaimer